CYP4F11

Across TCGA pan-cancer cohorts, CYP4F11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP4F11 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CYP4F11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CYP4F11 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

HNSC, CCRCC, and OV are the cancer types where CYP4F11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.140	1.000	.017	12	view →
CCRCC	OS	Median	All	0.638	1.000	.009	8	view →
OV	DFS	Median	All	0.655	1.000	.020	4	view →
PDAC	DFS	Tertile	II,III,IV	0.566	0.305	.018	4	view →
LUAD	DFS	Median	III,IV	0.315	0.913	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP4F11–HNSC (OS)

Open the HNSC breakdown →